|Articles|June 9, 2004
Santen Pharmaceuticals ends phaco device development
Phacor Inc., the California-based wholly owned subsidiary of Santen Pharmaceuticals Co. Ltd., ceased operations after 6 years of phacoemulsification system development.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5











































.png)


